Medera’s CTScreen™ Platform Installed At UMC Utrecht To Advance Cardiac Disease Research

Medera Inc. is a clinical-stage biopharmaceutical company focused on developing therapies to treat diseases that are presently untreatable. The company has recently announced the installation of its advanced CTScreen™ platform at the University Medical Center Utrecht (UMC Utrecht), along with its preclinical subsidiary Novoheart

"This technology enables unparalleled precision in understanding cardiac conditions. With UMC Utrecht’s expertise in regenerative medicine, we anticipate breakthroughs that will transform cardiovascular research," said Kevin Costa, Chief Scientific Officer and co-founder of Novoheart. 

The novel system enables Regenerative Medicine Center Utrecht to enhance its modeling capabilities for human cardiac conditions and improves their therapeutic development as well as their preclinical cardiac research. The investigators at UMC Utrecht will use CTScreen™ to study disease mechanisms, along with potential drug assessment and enhanced drug safety through Novoheart's human-based analytical tools.

Ronald Li, PhD, Chief Executive Officer and Founder of Medera, stated, “The installation at UMC Utrecht represents not only an expansion of Novoheart’s reach but also an exciting step in strengthening our partnership with this world-renowned institution. Together, we are exploring innovative possibilities in cardiac regeneration technologies that have the potential to redefine what’s possible in heart disease treatment. While today’s announcement marks a key milestone, we look forward to sharing more exciting developments soon as our collaboration deepens.”

Using the platform enables Novoheart to execute high-throughput screening of tissue samples at a rate of 96 simultaneously through its "mini-Heart™" technology. Through this development, Novoheart advances its existing alliances with AstraZeneca and Curi Bio while also supporting the FDA Modernization Act 2.0 initiative for human-based research alternatives.

“Our team is excited to bring the CTScreen™ system into our facility. This adds much-needed capabilities for measuring human cardiac tissue contractility, advancing our efforts in studying disease mechanisms and accelerating translation to clinical trials for patients with familial cardiomyopathies and other heart diseases that lack effective treatments,” said Joost Sluijter, PhD, Director of the Heart and Lung Division within the Regenerative Medicine Center Utrecht.